On Tuesday, May 19, the S&P 500 fell 0.42% to 7,372 while the Dow Jones Industrial Average held relatively steady, buoyed by a striking divergence: the Dogs of the Dow — the ten highest-yielding dividend stocks in the Dow 30 — are outperforming the broader market today. Dominion Energy surged on the NextEra acquisition, Home Depot reported earnings that beat estimates, and defensive names like Verizon, Chevron, and Coca-Cola are attracting buyers as AI-infrastructure stocks pull back for a second straight session. The question the market is now asking: is this the beginning of a genuine rotation from growth to value, and does it have enough momentum to push the Dow past 50,000 and hold it there?
The Dow vs. the S&P 500: They Are Not the Same Index
Most people treat the Dow and the S&P 500 as interchangeable gauges of the U.S. stock market. They are not. The differences between the two are fundamental, and they explain exactly why the Dow can outperform on a day when the S&P slides.
The Dow Jones Industrial Average is a price-weighted index of just 30 large-cap American companies. Price-weighted means a stock with a higher share price has more influence over the index than one with a lower price, regardless of market capitalization. Goldman Sachs, currently trading above $600, has an outsized impact on the Dow’s daily moves. Apple, despite being one of the world’s most valuable companies, has a relatively modest influence because of its lower per-share price post-split. The Dow was created in 1896 and remains the oldest U.S. stock market index. Its 30 components are selected by a committee and tend to skew toward established, dividend-paying industrial and financial companies — the kind of blue-chip names that have defined American business for generations.
The S&P 500 is a market-cap-weighted index of 500 companies. That means Apple, NVIDIA, Microsoft, Amazon, and Meta — the five largest companies in the world by market value — collectively drive a disproportionate share of its daily performance. Tech and AI-adjacent stocks account for roughly 30% of the S&P 500’s total weight. When NVIDIA falls 2%, the entire S&P 500 feels it. When Seagate drops 7% on supply-chain concerns — as happened Monday — Micron follows it down, and the Nasdaq and S&P both slide while the Dow, which has neither stock, shrugs.
This structural difference is precisely why today’s divergence is happening. During Monday’s session, the S&P 500 and Nasdaq slipped as a selloff in memory chip makers dragged both benchmarks lower for a second straight day, following a nearly 7% drop in Seagate shares after its CEO expressed concerns about factory buildout timing, while peer Micron also fell around 6%. The Dow, by contrast, rose 160 points or 0.32% to close at 49,686 — held up by energy, healthcare, and consumer staples names that have no exposure to the AI chip selloff.
What Are the Dogs of the Dow?
The Dogs of the Dow is one of the oldest and simplest investing strategies on Wall Street, popularized by investor Michael O’Higgins in the early 1990s. The rules are straightforward: at the start of each year, identify the 10 stocks in the Dow 30 with the highest dividend yields, invest equally in all 10, and hold for the full year. Rebalance and repeat.
The logic is contrarian. A high dividend yield may indicate that a blue-chip stock has become temporarily cheap after share-price weakness. Since these companies are part of the blue-chip Dow, investors also see them as relatively stable, higher-quality names. When yields rise, it can signal undervaluation — and a potential recovery when earnings stabilize.
The strategy had its strongest performance since 2019 in 2025, gaining 17% during the year, ahead of the Dow’s 13.7% return over the same stretch. After lagging the broader market in 2023 and 2024, the Dogs roared back. The average yield at the start of 2026 was 3.3%, more than twice the average of the S&P 500 Index.
The 2026 Dogs of the Dow are: Verizon (VZ), Chevron (CVX), UnitedHealth (UNH), Merck (MRK), Amgen (AMGN), Procter & Gamble (PG), Coca-Cola (KO), Home Depot (HD), Nike (NKE), and Johnson & Johnson (JNJ).
Stock-by-Stock Breakdown
Verizon (VZ) — Yield: 6.8% — Price: ~$46.85
The highest-yielding Dog and the most income-focused name on the list. Verizon’s Q1 2026 EPS of $1.28 beat estimates by 5.79%, with record adjusted EBITDA of $13.4 billion up 6.7% year-over-year and its highest EPS growth since 2021. The company recorded its first postpaid phone net adds in 13 years and free cash flow of $3.8 billion, up 4% year-over-year. The company maintains full-year guidance for $21.5B+ in free cash flow. Recent catalyst: AT&T, T-Mobile, and Verizon agreed in principle to form a new joint venture to address long-time coverage gaps in rural areas using satellite-based technology — a direct shot at Elon Musk’s Starlink. Price target raised to $52. Bernstein holds a Hold rating. The stock trades at just 8.5x 2026 earnings estimates — one of the cheapest valuations in the Dow.
Chevron (CVX) — Yield: 4.5% — Price: ~$158
The energy giant and Berkshire Hathaway holding is up more than 20% in 2026 alone, driven by oil prices surging above $109 per barrel amid the Iran conflict and Strait of Hormuz disruptions. Goldman Sachs raised its price target on Chevron to $216 from $211, keeping a Buy rating, citing strong free cash flow. Chevron is a Dividend Aristocrat that raised its dividend 4% entering 2026. The Iran peace deal risk is real — shares in Exxon, Chevron, and Occidental tumbled on signs the Trump administration is close to agreeing a peace deal — but for now, elevated oil prices are a powerful tailwind.
Home Depot (HD) — Yield: ~3% — Price: ~$299
HD reported Q1 fiscal 2026 earnings this morning — the freshest data point in the Dogs basket today. The Atlanta-based retailer posted adjusted EPS of $3.43, clearing Wall Street’s estimate of $3.41. Revenue came in at $41.77 billion, beating forecasts of roughly $41.59 billion and representing growth of approximately 5% compared to the same period last year. Home Depot reaffirmed its full fiscal 2026 guidance, calling for total sales growth of 2.5% to 4.5% and comparable sales growth of approximately flat to 2%. The fly in the ointment: same-store sales grew just 0.6%, missing the 0.9% expected, and CFO Richard McPhail cautioned that homeowners are pulling back on bigger-ticket projects, saying “they continue to tell us that they are going to defer their spend on larger projects.” The stock is down 21% over the past 12 months and 12% YTD, making it one of the more beaten-down Dogs. Wall Street maintains a Strong Buy consensus with an average price target of $403.58, implying 35% upside.
Merck (MRK) — Yield: ~3.5% — Price: ~$88
Merck is one of the healthcare names in the Dogs basket that analysts flagged as attractive heading into 2026 as regulatory concerns from Washington eased. The stock has been under pressure from Keytruda patent cliff concerns — the company’s blockbuster cancer drug faces biosimilar competition later this decade — but near-term earnings remain solid and the dividend is well-covered. One of three healthcare Dogs (alongside Amgen and JNJ) that collectively represent 40% of the basket’s weighting, making healthcare the dominant sector exposure in the strategy this year.
Amgen (AMGN) — Yield: ~3.2% — Price: ~$285
The biotech giant is one of the stronger performers in the Dogs basket YTD, lifted by its obesity drug pipeline and a rebound in healthcare sentiment. Amgen’s MariTide weight-loss drug is in late-stage trials and represents a potential multi-billion-dollar revenue stream. Amgen and Johnson & Johnson helped push the Dogs of the Dow higher in 2025, with both stocks up between 28% and 44% during the year. The dividend has grown consistently and the balance sheet, while carrying debt from the Horizon Therapeutics acquisition, is manageable against strong free cash flow generation.
Johnson & Johnson (JNJ) — Yield: ~3.1% — Price: ~$162
One of the most durable dividend growers in the market, JNJ has raised its dividend for over 60 consecutive years. The spinoff of Kenvue (its consumer health division) in 2023 left the remaining J&J as a purer pharmaceutical and MedTech play. The talc litigation overhang that plagued the stock for years has largely been resolved. JNJ is a classic safety trade in risk-off environments — and with the S&P sliding on AI chip concerns today, defensive capital is flowing exactly here.
Coca-Cola (KO) — Yield: ~3.0% — Price: ~$71
Warren Buffett’s most iconic holding and the definition of a Dividend Aristocrat. KO has raised its dividend annually for over 60 years. The stock is a beneficiary of its global pricing power — Coca-Cola products sell in virtually every country on earth, giving it a natural inflation hedge. In an environment where the 10-year Treasury yield is elevated and the Fed is on hold, KO’s 3% yield with near-zero business model risk is attracting conservative capital rotating out of high-multiple tech.
Procter & Gamble (PG) — Yield: ~2.6% — Price: ~$165
The consumer staples giant was the one Dog that finished 2025 in the red, making it the most contrarian pick in the basket heading into 2026. PG makes Tide, Gillette, Pampers, and dozens of other household staples — products whose demand is largely insensitive to economic cycles. The stock has lagged as input cost inflation squeezed margins, but pricing power has allowed gradual recovery. A classic defensive name that outperforms when growth stocks sell off.
Nike (NKE) — Yield: ~2.5% — Price: ~$56
The most troubled Dog. Nike joined the list because its stock has been crushed — down sharply from its peak — as the company has lost market share to On Running, Hoka, and New Balance, and struggled with its DTC pivot and inventory issues. New CEO Elliott Hill took over in late 2024 and is executing a turnaround, rebuilding wholesale relationships and refocusing on sport performance. Wall Street’s 12-month consensus price target implies 21% upside, but NKE is the Dog most at risk of being a value trap rather than a value opportunity. Tariff exposure on Asian manufacturing is also a near-term headwind.
UnitedHealth (UNH) — Yield: ~1.8% — Price: ~$290
The most dramatic story in the Dogs basket. UNH joined the list after one of the most stunning collapses of any Dow component in recent memory — the stock fell from above $600 to below $300 following the murder of CEO Brian Thompson in December 2024, which triggered a wave of public backlash against health insurance companies and accelerating government scrutiny of the sector. The company has since guided for at least $17.75 in adjusted EPS for 2026 but guided for revenue roughly $17 billion light of consensus. At current levels, the stock trades at one of its cheapest valuations in a decade — making it either the deepest value play in the basket or a value trap depending on how Washington’s healthcare policy debate evolves.
Is the Value Rotation Real?
Today’s divergence between the Dow and the S&P raises a question that strategists have been debating all year: is the AI trade concentration in the S&P creating a structural case for rotating into value and dividend stocks?
The argument for rotation is compelling. Tech stocks have contributed 85% of the S&P 500’s total return YTD, a level of concentration that historically precedes mean reversion. The 10-year Treasury yield hitting its highest level in a year makes dividend-paying stocks more attractive on a relative basis. With the 10-year Treasury yield near 4.46%, dividend shares must offer more than income — investors need evidence of free cash flow, manageable debt, stable earnings, and a dividend policy that can survive a slower revenue cycle. Several Dogs — Verizon, Chevron, Coca-Cola, JNJ — check all four boxes.
The argument against a sustained rotation is equally real. AI opportunity cost is the key test — the Dogs of the Dow basket may lag if AI earnings continue to accelerate and investors keep paying premium multiples for growth. If NVIDIA blows out earnings on Wednesday and guides above $85 billion for Q2, the AI trade roars back, growth money stays in tech, and the Dogs return to being afterthoughts. The strategy works best as a diversification tool, not a replacement for broad equity exposure.
Will the Dow Hit 50,000?
The Dow actually already crossed 50,000 for the first time ever on May 14 — rising more than 350 points to climb above the 50,000 level for the first time since February, driven by Goldman Sachs and Caterpillar doing most of the heavy lifting as usual, while NVIDIA surged more than 4% after U.S. regulators approved H200 chip sales to Chinese firms. Today the Dow sits at 49,686 — just 314 points below that milestone.
Whether it holds above 50,000 sustainably depends on the same forces driving today’s session. If Wednesday’s NVIDIA earnings deliver a beat-and-raise that restores confidence in the AI trade, the Dow gets the tech lift it needs from Goldman, Microsoft, and NVIDIA itself (added to the index in November 2024) to push back through 50,000 convincingly. The prior all-time high of around 50,500 would be the next target for bulls. If NVDA disappoints, the rotation into Dow defensives continues — but a defensive-led Dow rally is slower and less explosive than an AI-powered one.
The Dogs of the Dow outperforming on a down-S&P day is not a coincidence or noise. It is a signal that investors are beginning to hedge their AI concentration risk with the kinds of cash-generating, dividend-paying blue-chip businesses that have survived every recession, every market cycle, and every technological disruption for the past century. Whether that hedge becomes a full rotation depends on what Jensen Huang says on Wednesday evening.
This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
About the Author
